AvenCell Europe GmbH — CureCurrent

How to interpret these research links

Connected source records

The exact organization name AvenCell Europe GmbH appears in 3 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials3

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

3 shown

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA MarkerNCT04633148 · lead sponsor · 2020-11-23

TERMINATED

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA MarkerNCT03927573 · lead sponsor · 2019-04-15

TERMINATED

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsNCT07474051 · collaborator · 2026-01-29

ENROLLING_BY_INVITATION

Sponsor roles

lead sponsor2

collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.